Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

INTRODUCTION: The efficacy and safety of ixekizumab, an anti-interleukin-17A antibody, in patients with severe symptoms of psoriatic arthritis are largely unexplored. We report the efficacy and safety of ixekizumab in a post hoc analysis of the SPIRIT-P1 trial. METHODS: Patients were treated with pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kameda, Hideto, Hagimori, Kohei, Morisaki, Yoji, Holzkämper, Thorsten, Konomi, Ayako, Dobashi, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654305/
https://www.ncbi.nlm.nih.gov/pubmed/37858007
http://dx.doi.org/10.1007/s40744-023-00605-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654305/
https://www.ncbi.nlm.nih.gov/pubmed/37858007
http://dx.doi.org/10.1007/s40744-023-00605-6

Ejemplares similares